Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies

NCT02536755 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Gaucher Disease

Interventions

DRUG: Eliglustat, GZ385660

Sponsor

Genzyme, a Sanofi Company